Because of the low expression of B7-H3 in normal tissues, it has become a promising target for cancer immunotherapy, and several therapeutic strategies that target B7-H3, such as small-molecule inhibitors and chimeric antigen receptor T (CAR-T) cell technology, have been used for the treatment of cancer in clinical trials (Picarda et al., 2016). Here, CD276 is linked to cancer.